ANI Pharmaceuticals announces cash offer to acquire Egetis Therapeutics
ANI disclosed a $676 million bridge facility and a recommended public cash offer for Swedish drugmaker Egetis valued at roughly $559.9 million.
SEC filing
3 stories
ANI disclosed a $676 million bridge facility and a recommended public cash offer for Swedish drugmaker Egetis valued at roughly $559.9 million.
SEC filing
WAKIX net revenue reached $269 million in the quarter, and the company said it remains on track to meet full-year guidance of $1.0 billion to $1.04 billion.
SEC filing (2)